Earnings Routine +

Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M

Insider Debt Bridges Runway as Core Revenue Slips Ahead of Uncertain U.S. Uplisting

By The Northwire Desk — AI Analysis Mar 31, 2026 · 03:00 INNO · 6.59 InnoCan Pharma Corporation

Executive Summary

The most recent release on March 31, 2026, announces an additional US$200,000 secured debenture offering to Tamar Innovest Ltd., the company’s largest shareholder (17% stake) and an insider.
The instrument carries a 10% annual interest rate and matures at the earlier of 12 months from issuance or the completion of the company’s proposed U.S. public offering under its Form F-1.
Proceeds are designated for working capital and general corporate purposes. This follows a nearly identical US$450,000 debenture announced on March 11 and closed on March 16, 2026.
Concurrently, the company reported FY2025 audited financials showing revenues of US$26.6M, a 9.6% year-over-year decline, though gross margins expanded slightly to 89.9%. Operating losses remained flat at approximately US$1.255M.
Management highlighted moderating sales declines, cost-saving supply chain adjustments, and ongoing preparations for the NYSE American listing.
Historical context shows a steady progression toward a U.S. uplisting: an amended F-1 was filed in December 2025 with ThinkEquity as bookrunner, followed by an anticipated NYSE American listing announcement in January 2026. Pipeline updates include a third consecutive FDA CVM fee waiver for LPT-CBD in February 2026 and a Japanese patent allowance in October 2025.

Material Impact

The $200,000 debenture is a routine, incremental financing that does not alter the company’s fundamental trajectory or valuation. It is a direct follow-up to the March 11 offering and serves as a short-term liquidity bridge.
The reliance on insider debt at a 10% interest rate signals constrained access to traditional institutional capital markets and highlights immediate working capital needs ahead of the U.S. offering.
FY2025 financials confirm a stable but contracting core business. While gross margins remain exceptionally high (~90%), the consistent ~10% revenue decline and flat operating losses indicate a mature, low-growth consumer wellness segment that is not generating sufficient free cash flow to fund the LPT-CBD pipeline independently.
The U.S. public offering remains the primary catalyst. Until the F-1 becomes effective and the offering closes, the company will likely continue to rely on piecemeal insider financing to cover listing costs and operational burn.
Overall, the news is expected and routine. It provides minor balance sheet relief but introduces additional debt service obligations and underscores execution risk surrounding the delayed U.S. listing.

INNO · Price

Company Overview

Innocan Pharma operates a dual-segment business: a consumer wellness joint venture (B.I. Sky Global, 60% owned) generating current revenues, and a biotechnology pipeline focused on Liposome Platform Technology-Cannabidiol (LPT-CBD).
The flagship project is LPT-CBD, a sustained-release, subcutaneous liposomal formulation targeting chronic pain in both veterinary and human markets.
Development has progressed through preclinical animal models (goats, dogs) demonstrating sustained plasma levels, favorable safety profiles (no liver enzyme elevation), and statistically significant pain reduction.
The company holds granted or allowed patents in India and Japan, with a broader international IP portfolio under examination.
The strategic pivot toward a U.S. public listing aims to secure capital for IND-enabling studies and eventual FDA approval for human chronic pain applications.

More from InnoCan Pharma Corporation